Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia

Daniel Casey

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Neuroleptics were the first modem class of pharmacotherapeutic agents available for the treatment of schizophrenia. Although they were effective in reducing florid psychotic symptoms, up to 90% of treated individuals subsequently developed extrapyramidal symptoms (EPS) (akathisia, dystonia, or parkinsonism), and about 20% developed tardive dyskinesia (TD). When clozapine became commercially available for treatment-resistant and treatment-intolerant (i.e., prone to EPS and TD) schizophrenic individuals, it became apparent that an antipsychotic need not induce motor side effects to be efficacious in reducing the symptomatology of schizophrenia. Sociodemographic, behavioral, and clinical predictors of TD are useful in identifying a subset of schizophrenic individuals who would benefit from treatment with clozapine, the prototype atypical antipsychotic whose efficacy and motor side effect profile are superior to those of chlorpromazine. This favorable motor side effect profile of clozapine contributes to improved patient outcomes by reducing noncompliance, substance abuse, and suicide, resulting in improved quality of life and savings on health care costs.

Original languageEnglish (US)
Pages (from-to)31-37
Number of pages7
JournalJournal of Clinical Psychiatry
Volume59
Issue numberSUPPL. 3
StatePublished - 1998

Fingerprint

Clozapine
Antipsychotic Agents
Schizophrenia
Modems
Psychomotor Agitation
Dystonia
Chlorpromazine
Parkinsonian Disorders
Therapeutics
Health Care Costs
Suicide
Substance-Related Disorders
Quality of Life
Tardive Dyskinesia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia. / Casey, Daniel.

In: Journal of Clinical Psychiatry, Vol. 59, No. SUPPL. 3, 1998, p. 31-37.

Research output: Contribution to journalArticle

@article{22a1e82d45684b1ba52da92d7cd2941b,
title = "Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia",
abstract = "Neuroleptics were the first modem class of pharmacotherapeutic agents available for the treatment of schizophrenia. Although they were effective in reducing florid psychotic symptoms, up to 90{\%} of treated individuals subsequently developed extrapyramidal symptoms (EPS) (akathisia, dystonia, or parkinsonism), and about 20{\%} developed tardive dyskinesia (TD). When clozapine became commercially available for treatment-resistant and treatment-intolerant (i.e., prone to EPS and TD) schizophrenic individuals, it became apparent that an antipsychotic need not induce motor side effects to be efficacious in reducing the symptomatology of schizophrenia. Sociodemographic, behavioral, and clinical predictors of TD are useful in identifying a subset of schizophrenic individuals who would benefit from treatment with clozapine, the prototype atypical antipsychotic whose efficacy and motor side effect profile are superior to those of chlorpromazine. This favorable motor side effect profile of clozapine contributes to improved patient outcomes by reducing noncompliance, substance abuse, and suicide, resulting in improved quality of life and savings on health care costs.",
author = "Daniel Casey",
year = "1998",
language = "English (US)",
volume = "59",
pages = "31--37",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia

AU - Casey, Daniel

PY - 1998

Y1 - 1998

N2 - Neuroleptics were the first modem class of pharmacotherapeutic agents available for the treatment of schizophrenia. Although they were effective in reducing florid psychotic symptoms, up to 90% of treated individuals subsequently developed extrapyramidal symptoms (EPS) (akathisia, dystonia, or parkinsonism), and about 20% developed tardive dyskinesia (TD). When clozapine became commercially available for treatment-resistant and treatment-intolerant (i.e., prone to EPS and TD) schizophrenic individuals, it became apparent that an antipsychotic need not induce motor side effects to be efficacious in reducing the symptomatology of schizophrenia. Sociodemographic, behavioral, and clinical predictors of TD are useful in identifying a subset of schizophrenic individuals who would benefit from treatment with clozapine, the prototype atypical antipsychotic whose efficacy and motor side effect profile are superior to those of chlorpromazine. This favorable motor side effect profile of clozapine contributes to improved patient outcomes by reducing noncompliance, substance abuse, and suicide, resulting in improved quality of life and savings on health care costs.

AB - Neuroleptics were the first modem class of pharmacotherapeutic agents available for the treatment of schizophrenia. Although they were effective in reducing florid psychotic symptoms, up to 90% of treated individuals subsequently developed extrapyramidal symptoms (EPS) (akathisia, dystonia, or parkinsonism), and about 20% developed tardive dyskinesia (TD). When clozapine became commercially available for treatment-resistant and treatment-intolerant (i.e., prone to EPS and TD) schizophrenic individuals, it became apparent that an antipsychotic need not induce motor side effects to be efficacious in reducing the symptomatology of schizophrenia. Sociodemographic, behavioral, and clinical predictors of TD are useful in identifying a subset of schizophrenic individuals who would benefit from treatment with clozapine, the prototype atypical antipsychotic whose efficacy and motor side effect profile are superior to those of chlorpromazine. This favorable motor side effect profile of clozapine contributes to improved patient outcomes by reducing noncompliance, substance abuse, and suicide, resulting in improved quality of life and savings on health care costs.

UR - http://www.scopus.com/inward/record.url?scp=0031957496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031957496&partnerID=8YFLogxK

M3 - Article

C2 - 9541336

AN - SCOPUS:0031957496

VL - 59

SP - 31

EP - 37

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - SUPPL. 3

ER -